Meet The Team
Alex Ringo
Alex Ringo, co-founder and CEO of Diatomic Inc., brings expertise in market segmentation and differentiation, M&A, and pipeline strategy. Previously, he held commercial and technical roles at Abbott and LifeCell (an Allergan Company), where he drove device design, international product launches, and product management. Alex holds an MBA from Duke University’s Fuqua School of Business and an advanced degree in Biomedical Engineering from the University of Rochester. He is an author on multiple regenerative medicine patents, contributing to advancements in the field.
Israel Jessop
Israel J. Jessop, co-founder and CTO of Diatomic Inc., brings 25 years of medtech expertise to our mission of revolutionizing organ preservation. With leadership experience at Johnson & Johnson, AbbVie, and Vascular Perfusion Solutions, Israel drives our innovative hydrogen-based therapies to extend organ viability and improve transplant outcomes. A prolific inventor with over 20 patents, he has been honored as Innovator of the Year (2015, 2016) at LifeCell for his groundbreaking work in medical devices and tissue engineering. Holding a B.S. in Metallurgical Engineering from Montana Tech and an M.S. in Materials Science from The University of Florida, Israel leads our team with a passion for solving complex challenges and advancing patient care worldwide.
Nick Shea
Dr. Nicholas J. Shea, Chief Medical Officer of Diatomic Inc., is a distinguished cardiac surgeon and innovator, serving as Chief of Cardiac Surgery and Co-Director of the Heart and Vascular Institute at Stamford Health, and Assistant Professor of Surgery at Columbia University Irving Medical Center. With expertise in mitral valve repair, complex aortic arch and root disease, multi-arterial coronary bypass, heart failure, and orthotopic heart and lung transplantation, Dr. Shea brings unparalleled clinical insight to our mission of advancing organ preservation. Holding an MD and M.S. in Biomedical Engineering from Columbia University, he has published extensively on aortic disease, heart failure, and surgical innovation, while contributing to numerous device patents. Board-certified by the American Board of Thoracic Surgery and a fellow of the American College of Cardiology, Dr. Shea drives Diatomic’s development of hydrogen-based therapies to revolutionize heart transplant outcomes.
James Silver
James Silver, Chief Legal, Regulatory and Administrative Officer at Diatomic Inc., brings a wealth of experience as a corporate and technology transactions lawyer and C-suite executive to drive our mission of delivering innovative heart preservation solutions. With a robust background spanning the lifecycle of life sciences companies, James has held pivotal roles, including Chief Legal, Regulatory and Administrative Officer at Cognoa, Chief Operating Officer at Oligon Inc., and Vice President of Corporate Development at Systems Oncology, where he executed complex transactions like nine-figure licensing deals. His expertise in legal affairs, intellectual property, regulatory compliance, and international expansion, combined with leadership in business development and operations, uniquely positions him to navigate the legal and regulatory landscape for Diatomic’s groundbreaking hydrogen-based therapies, ensuring safer and more efficient heart transplant outcomes. James holds a law degree from the University of London, and practiced at Wilson Sonsini.